Development status: Approved, off-patent, discontinued in many countries

Gram-positive activity

Mechanism of Action/Target pathogen: Binds to the bacterial 50S ribosomal subunit and inhibits the elongation process of protein synthesis

Additional information: Natural compound produced by Streptomyces. Mixture of pristinamycin IA (macrolide) and pristinamycin IIA (depsipeptide streptogramin A). Oral formulation.